Impact of Pyridoxamine on Bone Health in Elderly Women with Type 2 Diabetes
Overview
In a randomized controlled trial of older women with type 2 diabetes, pyridoxamine treatment increased bone formation marker P1NP by 23% and improved femoral neck bone mineral density compared to placebo. Additionally, pyridoxamine reduced HbA1c levels, suggesting potential dual benefits on bone health and glycemic control.
Background
Patients with type 2 diabetes have an increased risk of fractures despite normal or elevated bone mineral density, likely due to reduced bone turnover and accumulation of advanced glycation end products (AGEs) that impair osteoblast function. Pyridoxamine, a vitamin B6 metabolite, inhibits AGE formation and has shown promise in preclinical models for improving bone mechanical properties. This study evaluated the effects of pyridoxamine on bone formation and density in older women with type 2 diabetes.
Data Highlights
Outcome
Pyridoxamine Group
Placebo Group
Between Groups P Value
Change in P1NP (%)
+23.0% (95% CI 9, 37; P = .028)
+4.1% (95% CI −9, 17; P = .576)
0.056
Change in Femoral Neck BMD (%)
+2.6 ± 5%
−0.9 ± 4%
0.007
Change in HbA1c (%)
−0.38 ± 0.7%
+0.05 ± 1.7%
0.04
Bone Resorption Markers
No significant change
No significant change
Not significant
Skin Autofluorescence (SAF)
No significant change
No significant change
Not significant
Key Findings
Pyridoxamine increased the bone formation marker P1NP by 23% over 1 year compared to 4.1% with placebo.
Femoral neck bone mineral density increased by 2.6% in the pyridoxamine group versus a 0.9% decrease in placebo.
HbA1c levels decreased significantly with pyridoxamine treatment compared to placebo.
Bone resorption markers and skin autofluorescence did not change significantly in either group.
Bone fluorescent AGEs measured in biopsies correlated strongly with skin autofluorescence, validating SAF as a marker of AGE accumulation.
Adverse events were similar between pyridoxamine and placebo groups, indicating good tolerability.
Clinical Implications
Pyridoxamine may represent a novel therapeutic approach to improve bone formation and density in older women with type 2 diabetes by inhibiting AGE accumulation. Its additional benefit in lowering HbA1c suggests potential dual effects on bone health and glycemic control. Further studies are warranted to confirm these findings and evaluate fracture risk reduction.
Conclusion
Pyridoxamine treatment in elderly women with type 2 diabetes showed promising effects in increasing bone formation and femoral neck bone density while improving glycemic control. These results support further investigation of pyridoxamine as a disease mechanism–targeted therapy for diabetic bone disease.
References
Authors/Source/2024 -- Impact of Pyridoxamine, an AGE Inhibitor, on Bone Health in Elderly Women with Type 2 Diabetes: Results from a Randomized Clinical Trial
by Aiden V Brossfield, Donald J McMahon, Jason Fernando, Beatriz Omeragic, Rukshana Majeed, Sanchita Agarwal, Grazyna E Sroga, Bowen Wang, Deepak Vashishth, Mishaela R Rubin
A large audit of biomedical publications suggests fabricated references are increasingly appearing in peer-reviewed papers — often in ways that are difficult for reviewers and readers to detect.
